Evidence map›Paper›PMID 31471409›Full record

ArticleIn vivo (Athens, Greece)

Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.

Stefania Stella, Elena Tirró, Michele Massimino, Silvia Rita Vitale, Sabina Russo, Maria Stella Pennisi, Adriana Puma, Chiara Romano, Sandra DI Gregorio, Vanessa Innao and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stefania Stella *Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy stefania.stel@gmail.com.
Elena Tirró *Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Michele Massimino *Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Silvia Rita VitaleDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Sabina RussoDivision of Hematology, University of Messina, Messina, Italy.
Maria Stella PennisiDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Adriana PumaDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Chiara RomanoDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Sandra DI GregorioDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Vanessa InnaoDivision of Hematology, University of Messina, Messina, Italy.
Fabio StagnoDivision of Hematology and Bone Marrow Transplant, A.O.U. Policlinico-Vittorio Emanuele, Catania, Italy.
Francesco DI RaimondoDivision of Hematology and Bone Marrow Transplant, A.O.U. Policlinico-Vittorio Emanuele, Catania, Italy.
Caterina MusolinoDivision of Hematology, University of Messina, Messina, Italy.
Livia ManzellaDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAs approximately 10% of individuals developing chronic myeloid leukemia (CML) are females aged 20-44 years, a considerable number will consider a planned pregnancy if disease is well controlled by pharmacological treatment. The management of these young patients during pregnancy represents a therapeutic dilemma due to the potential teratogen effects of several tyrosine kinase inhibitors (TKIs) and is a matter of continuous debate. Indeed, despite the existence of several studies, there is currently no consensus on how to manage different pregnancy situations in subjects with CML. PATIENTS AND

methodsWe describe a female patient diagnosed with Ph-positive CML one month after her first delivery who achieved excellent hematological, cytogenetic and molecular responses while on imatinib mesylate (IM) treatment.

resultsThe excellent responses allowed the patient to suspend TKI treatment in order to plan a second pregnancy. Despite IM discontinuation, stringent molecular monitoring of her BCR-ABL1/ABL1 levels allowed the safe delivery of the child and, while the patient eventually developed a molecular relapse after four years of treatment discontinuation, upon restarting IM she quickly regained a deep molecular response that is still ongoing.

conclusionOur case report demonstrates that, if the pregnancy is properly planned in CML patients, it can result in excellent management of the clinical therapeutic option for the benefit of both mother and child.

Indexed as

AdultAntineoplastic AgentsBiomarkersBiopsyFemaleFusion Proteins, bcr-ablHumansImatinib MesylateIn Situ Hybridization, FluorescenceLeukemia, Myelogenous, Chronic, BCR-ABL PositivePregnancyPregnancy Complications, NeoplasticProtein Kinase InhibitorsTreatment OutcomeAntineoplastic AgentsBiomarkersFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsBCR-ABL1chronic myeloid leukemiaimatinib mesylatePregnancy

Identifiers

PMID31471409
PMCPMC6755009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.